Some rectal cancer patients can now skip surgery, chemo and radiation after FDA approves Jemperli
In a 154-patient trial, 71% of patients were treated with the immunotherapy alone and needed nothing else by the data cutoff. The approval covers only tumors with a specific DNA repair defect, about 3% of locally advanced rectal cancers.
Source: FDA press release, Oct 19, 2026




